Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
7.31
+0.79 (12.12%)
Mar 9, 2026, 2:46 PM EDT - Market open
Edesa Biotech Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| Selling, General & Admin | 4.58 | 4.24 | 4.13 | 4.43 | 5.04 | 5.73 | |
| Research & Development | 3.77 | 3.67 | 2.88 | 4.79 | 13.34 | 17.95 | |
| Operating Expenses | 8.35 | 7.91 | 7.01 | 9.22 | 18.37 | 23.68 | |
| Operating Income | -8.35 | -7.91 | -7.01 | -9.22 | -18.37 | -23.68 | |
| Interest & Investment Income | 0 | 0 | 0.15 | 0.29 | 0.06 | 0.01 | |
| Currency Exchange Gain (Loss) | -0.05 | -0.06 | -0.02 | -0.02 | -0.02 | -0.01 | |
| EBT Excluding Unusual Items | -8.4 | -7.97 | -6.88 | -8.95 | -18.33 | -23.68 | |
| Other Unusual Items | 0.59 | 0.78 | 0.71 | 0.58 | 0.78 | 10.34 | |
| Pretax Income | -7.82 | -7.18 | -6.17 | -8.37 | -17.55 | -13.34 | |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Income | -7.82 | -7.19 | -6.17 | -8.37 | -17.55 | -13.34 | |
| Net Income to Common | -7.82 | -7.19 | -6.17 | -8.37 | -17.55 | -13.34 | |
| Shares Outstanding (Basic) | 7 | 6 | 3 | 3 | 2 | 2 | |
| Shares Outstanding (Diluted) | 7 | 6 | 3 | 3 | 2 | 2 | |
| Shares Change (YoY) | 110.15% | 77.54% | 11.84% | 36.37% | 21.50% | 40.32% | |
| EPS (Basic) | -1.14 | -1.27 | -1.93 | -2.93 | -8.37 | -7.73 | |
| EPS (Diluted) | -1.14 | -1.27 | -1.93 | -2.93 | -8.37 | -7.73 | |
| Free Cash Flow | -7.89 | -7.32 | -4.89 | -6.64 | -12.28 | -13.67 | |
| Free Cash Flow Per Share | -1.16 | -1.29 | -1.53 | -2.32 | -5.86 | -7.92 | |
| EBITDA | -8.25 | -7.79 | -6.83 | -9.12 | -18.26 | -23.57 | |
| D&A For EBITDA | 0.1 | 0.12 | 0.19 | 0.11 | 0.11 | 0.11 | |
| EBIT | -8.35 | -7.91 | -7.01 | -9.22 | -18.37 | -23.68 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.